CAR-T
FDA places hold on Ziopharm CAR-T trial
June 19, 2018Manufacturing and Production, Research and Development CAR-T, FDA, pharma, ziopharm
CAR-T is emerging as one of the most potentially exciting therapies in the industry, particularly as a beacon for the …
Looking to the future of oncology
April 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, oncology, pharma
The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves …
bluebird backs own CAR-T prospect, takes option to co-develop with Celgene
March 29, 2018Sales and Marketing Bluebird Bio, CAR T, CAR-T, Celgene, biotech, drugs, pharma, pharmaceutical
Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …
Gilead seals $3bn deal, hoping for off-the-shelf CAR-T
February 23, 2018Medical Communications, Sales and Marketing CAR-T, Gilead, Kite, Sangamo Therapeutics, biotech, drugs, pharma, pharmaceutical
The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …
Celgene confirms rumours, with $9bn deal for Juno
January 22, 2018Manufacturing and Production, Sales and Marketing CAR-T, Celgene, biotech, drugs, juno therapeutics, pharma, pharmaceutical
It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on …
Top Ten most popular articles on Pharmafile.com this week
January 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten
It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …
Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US
January 17, 2018Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma
Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …
Celgene rumoured to be revving up for Juno buyout
January 17, 2018Research and Development, Sales and Marketing CAR-T, Celgene, Juno, biotech, drugs, pharma, pharmaceutical
Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …
Gilead makes $567m strategic acquisition for next-gen CAR-T
December 8, 2017Medical Communications, Sales and Marketing CAR-T, Cell Design Labs, Gilead, Kite, biotech, drugs, pharma, pharmaceutical
It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …
Promising new CAR-T therapy able to target T-cell lymphoma
November 15, 2017Research and Development Autolus, CAR T, CAR-T, biotech, drugs, pharma, pharmaceutical
The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to …
Cellectis given another shot at off-the-shelf CAR-T
November 8, 2017Medical Communications, Research and Development CAR-T, biotech, cellectis, drugs, pharma, pharmaceutical
It is easy to forget the very real dangers that CAR-T treatment present to patients after Novartis and Gilead both …
Novartis aims for CAR-T double-approval in Europe
November 6, 2017Sales and Marketing CAR-T, Gilead, Juno, Novartis, biotech, drugs, pharma, pharmaceutical
Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …
Novartis reveals the data behind its showdown with Gilead
November 1, 2017Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical
Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …
CAR-T is bringing true precision to the fight against cancer
November 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta
Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …
Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell lymphoma
October 31, 2017Manufacturing and Production, Sales and Marketing CAR-T, Kymriah, Novartis
Following the “historic” FDA approval of the company’s CAR-T therapy Kymriah (tisagenlecleucel) in the treatment of paediatric and young adults …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
